NO331935B1 - Modifisert faktor VIII, DNA, ekspresjonsvektor, terapeutisk preparat, metode for a produsere modifisert svin-faktor VIII-protein, samt vertcelle - Google Patents

Modifisert faktor VIII, DNA, ekspresjonsvektor, terapeutisk preparat, metode for a produsere modifisert svin-faktor VIII-protein, samt vertcelle Download PDF

Info

Publication number: NO331935B1
Authority: NO; Norway
Prior art keywords: factor viii; porcine; human; factor; dna
Prior art date: 2000-03-10

Application number

NO20024296A

Other languages

English (en)

Norwegian (no)

Other versions

NO20024296D0 (no

NO20024296L (no

Inventor

John S Lollar

Original Assignee

Univ Emory

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-03-10

Filing date

2002-09-09

Publication date

2012-05-07

2002-09-09 Application filed by Univ Emory filed Critical Univ Emory

2002-09-09 Publication of NO20024296D0 publication Critical patent/NO20024296D0/no

2002-11-08 Publication of NO20024296L publication Critical patent/NO20024296L/no

2012-05-07 Publication of NO331935B1 publication Critical patent/NO331935B1/no

Links

102000001690 Factor VIII Human genes 0.000 title claims abstract description 254
229960000301 factor viii Drugs 0.000 title claims abstract description 251
108010054218 Factor VIII Proteins 0.000 title claims abstract description 250
238000000034 method Methods 0.000 title claims description 39
238000002360 preparation method Methods 0.000 title claims description 19
239000013604 expression vector Substances 0.000 title claims description 15
230000001225 therapeutic effect Effects 0.000 title claims description 11
150000001413 amino acids Chemical class 0.000 claims description 58
108090000623 proteins and genes Proteins 0.000 claims description 57
102000004169 proteins and genes Human genes 0.000 claims description 45
125000003275 alpha amino acid group Chemical group 0.000 claims description 42
239000002773 nucleotide Substances 0.000 claims description 26
125000003729 nucleotide group Chemical group 0.000 claims description 26
108010076504 Protein Sorting Signals Proteins 0.000 claims description 17
239000013598 vector Substances 0.000 claims description 14
238000004519 manufacturing process Methods 0.000 claims description 9
241000282898 Sus scrofa Species 0.000 abstract description 22
208000009292 Hemophilia A Diseases 0.000 abstract description 18
208000031220 Hemophilia Diseases 0.000 abstract description 6
230000000694 effects Effects 0.000 description 66
210000004027 cell Anatomy 0.000 description 65
235000001014 amino acid Nutrition 0.000 description 59
108020004414 DNA Proteins 0.000 description 58
239000002299 complementary DNA Substances 0.000 description 58
101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 52
238000003752 polymerase chain reaction Methods 0.000 description 52
239000000047 product Substances 0.000 description 48
210000002381 plasma Anatomy 0.000 description 46
239000013615 primer Substances 0.000 description 46
102000057593 human F8 Human genes 0.000 description 41
229960000900 human factor viii Drugs 0.000 description 41
235000018102 proteins Nutrition 0.000 description 39
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 38
239000012634 fragment Substances 0.000 description 38
102000002110 C2 domains Human genes 0.000 description 33
108050009459 C2 domains Proteins 0.000 description 31
230000014509 gene expression Effects 0.000 description 27
239000003112 inhibitor Substances 0.000 description 26
238000012360 testing method Methods 0.000 description 24
108090000190 Thrombin Proteins 0.000 description 23
241001465754 Metazoa Species 0.000 description 22
229960004072 thrombin Drugs 0.000 description 22
230000002401 inhibitory effect Effects 0.000 description 21
239000002609 medium Substances 0.000 description 21
230000015271 coagulation Effects 0.000 description 20
238000005345 coagulation Methods 0.000 description 20
BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 20
239000011780 sodium chloride Substances 0.000 description 19
210000004369 blood Anatomy 0.000 description 18
239000008280 blood Substances 0.000 description 18
238000006243 chemical reaction Methods 0.000 description 17
238000002474 experimental method Methods 0.000 description 15
239000013612 plasmid Substances 0.000 description 14
201000003542 Factor VIII deficiency Diseases 0.000 description 13
108091034117 Oligonucleotide Proteins 0.000 description 13
108010048049 Factor IXa Proteins 0.000 description 12
238000003556 assay Methods 0.000 description 12
238000003776 cleavage reaction Methods 0.000 description 12
238000004128 high performance liquid chromatography Methods 0.000 description 12
230000007017 scission Effects 0.000 description 12
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 11
102100026735 Coagulation factor VIII Human genes 0.000 description 11
108020004705 Codon Proteins 0.000 description 11
238000002703 mutagenesis Methods 0.000 description 11
231100000350 mutagenesis Toxicity 0.000 description 11
239000000523 sample Substances 0.000 description 11
238000012163 sequencing technique Methods 0.000 description 11
238000005516 engineering process Methods 0.000 description 10
238000001802 infusion Methods 0.000 description 10
238000002955 isolation Methods 0.000 description 10
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 10
101800001401 Activation peptide Proteins 0.000 description 9
102400000069 Activation peptide Human genes 0.000 description 9
108091003079 Bovine Serum Albumin Proteins 0.000 description 9
108010014173 Factor X Proteins 0.000 description 9
108091028043 Nucleic acid sequence Proteins 0.000 description 9
238000007820 coagulation assay Methods 0.000 description 9
238000010276 construction Methods 0.000 description 9
230000007547 defect Effects 0.000 description 9
238000003780 insertion Methods 0.000 description 9
230000037431 insertion Effects 0.000 description 9
241000894007 species Species 0.000 description 9
210000000952 spleen Anatomy 0.000 description 9
108010061932 Factor VIIIa Proteins 0.000 description 8
108010074860 Factor Xa Proteins 0.000 description 8
208000032843 Hemorrhage Diseases 0.000 description 8
241000276498 Pollachius virens Species 0.000 description 8
208000034158 bleeding Diseases 0.000 description 8
230000000740 bleeding effect Effects 0.000 description 8
239000000872 buffer Substances 0.000 description 8
239000000701 coagulant Substances 0.000 description 8
239000000470 constituent Substances 0.000 description 8
239000012091 fetal bovine serum Substances 0.000 description 8
230000006870 function Effects 0.000 description 8
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 8
229920000053 polysorbate 80 Polymers 0.000 description 8
230000002947 procoagulating effect Effects 0.000 description 8
238000000746 purification Methods 0.000 description 8
238000011084 recovery Methods 0.000 description 8
230000002829 reductive effect Effects 0.000 description 8
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 7
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 7
230000004913 activation Effects 0.000 description 7
230000000692 anti-sense effect Effects 0.000 description 7
239000003153 chemical reaction reagent Substances 0.000 description 7
238000010367 cloning Methods 0.000 description 7
230000035602 clotting Effects 0.000 description 7
238000003757 reverse transcription PCR Methods 0.000 description 7
108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 6
241000588724 Escherichia coli Species 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
102100034343 Integrase Human genes 0.000 description 6
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 6
108010006785 Taq Polymerase Proteins 0.000 description 6
235000004279 alanine Nutrition 0.000 description 6
125000000539 amino acid group Chemical group 0.000 description 6
239000001110 calcium chloride Substances 0.000 description 6
229910001628 calcium chloride Inorganic materials 0.000 description 6
235000011148 calcium chloride Nutrition 0.000 description 6
230000002950 deficient Effects 0.000 description 6
238000004925 denaturation Methods 0.000 description 6
230000036425 denaturation Effects 0.000 description 6
238000010494 dissociation reaction Methods 0.000 description 6
230000005593 dissociations Effects 0.000 description 6
238000002372 labelling Methods 0.000 description 6
230000036961 partial effect Effects 0.000 description 6
150000003904 phospholipids Chemical class 0.000 description 6
108010047303 von Willebrand Factor Proteins 0.000 description 6
102100036537 von Willebrand factor Human genes 0.000 description 6
229960001134 von willebrand factor Drugs 0.000 description 6
206010053567 Coagulopathies Diseases 0.000 description 5
108091026890 Coding region Proteins 0.000 description 5
239000007995 HEPES buffer Substances 0.000 description 5
229930182555 Penicillin Natural products 0.000 description 5
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 5
239000002253 acid Substances 0.000 description 5
230000003321 amplification Effects 0.000 description 5
238000004458 analytical method Methods 0.000 description 5
230000037396 body weight Effects 0.000 description 5
238000004587 chromatography analysis Methods 0.000 description 5
239000001963 growth medium Substances 0.000 description 5
239000000203 mixture Substances 0.000 description 5
238000003199 nucleic acid amplification method Methods 0.000 description 5
229940049954 penicillin Drugs 0.000 description 5
239000000825 pharmaceutical preparation Substances 0.000 description 5
230000002441 reversible effect Effects 0.000 description 5
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
229960005322 streptomycin Drugs 0.000 description 5
108020005345 3' Untranslated Regions Proteins 0.000 description 4
108020003589 5' Untranslated Regions Proteins 0.000 description 4
101100313763 Arabidopsis thaliana TIM22-2 gene Proteins 0.000 description 4
241000699800 Cricetinae Species 0.000 description 4
108010014172 Factor V Proteins 0.000 description 4
108010054964 H-hexahydrotyrosyl-alanyl-arginine-4-nitroanilide Proteins 0.000 description 4
101000993321 Homo sapiens Complement C2 Proteins 0.000 description 4
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
108010000499 Thromboplastin Proteins 0.000 description 4
102000002262 Thromboplastin Human genes 0.000 description 4
241000700605 Viruses Species 0.000 description 4
HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 4
230000000890 antigenic effect Effects 0.000 description 4
208000015294 blood coagulation disease Diseases 0.000 description 4
238000004113 cell culture Methods 0.000 description 4
230000009852 coagulant defect Effects 0.000 description 4
230000000295 complement effect Effects 0.000 description 4
239000012228 culture supernatant Substances 0.000 description 4
230000007812 deficiency Effects 0.000 description 4
238000001514 detection method Methods 0.000 description 4
238000011161 development Methods 0.000 description 4
238000010790 dilution Methods 0.000 description 4
239000012895 dilution Substances 0.000 description 4
238000004108 freeze drying Methods 0.000 description 4
239000000499 gel Substances 0.000 description 4
230000002068 genetic effect Effects 0.000 description 4
150000002632 lipids Chemical class 0.000 description 4
239000000463 material Substances 0.000 description 4
230000001404 mediated effect Effects 0.000 description 4
108020004707 nucleic acids Proteins 0.000 description 4
102000039446 nucleic acids Human genes 0.000 description 4
150000007523 nucleic acids Chemical class 0.000 description 4
108090000765 processed proteins & peptides Proteins 0.000 description 4
239000011541 reaction mixture Substances 0.000 description 4
230000009257 reactivity Effects 0.000 description 4
210000002966 serum Anatomy 0.000 description 4
238000006467 substitution reaction Methods 0.000 description 4
238000001890 transfection Methods 0.000 description 4
PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 3
108010088751 Albumins Proteins 0.000 description 3
102000009027 Albumins Human genes 0.000 description 3
241000699802 Cricetulus griseus Species 0.000 description 3
108010017826 DNA Polymerase I Proteins 0.000 description 3
102000004594 DNA Polymerase I Human genes 0.000 description 3
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
238000002965 ELISA Methods 0.000 description 3
102000003960 Ligases Human genes 0.000 description 3
108090000364 Ligases Proteins 0.000 description 3
241001529936 Murinae Species 0.000 description 3
101800004937 Protein C Proteins 0.000 description 3
102000017975 Protein C Human genes 0.000 description 3
101800001700 Saposin-D Proteins 0.000 description 3
229920002684 Sepharose Polymers 0.000 description 3
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 3
238000002835 absorbance Methods 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 3
229960000723 ampicillin Drugs 0.000 description 3
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
230000008901 benefit Effects 0.000 description 3
230000008827 biological function Effects 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
238000012512 characterization method Methods 0.000 description 3
239000003593 chromogenic compound Substances 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
239000012141 concentrate Substances 0.000 description 3
230000009260 cross reactivity Effects 0.000 description 3
238000012217 deletion Methods 0.000 description 3
230000037430 deletion Effects 0.000 description 3
239000000975 dye Substances 0.000 description 3
239000003623 enhancer Substances 0.000 description 3
238000009396 hybridization Methods 0.000 description 3
230000002163 immunogen Effects 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
210000003292 kidney cell Anatomy 0.000 description 3
210000004962 mammalian cell Anatomy 0.000 description 3
210000001672 ovary Anatomy 0.000 description 3
239000002243 precursor Substances 0.000 description 3
239000003805 procoagulant Substances 0.000 description 3
229960000856 protein c Drugs 0.000 description 3
230000006337 proteolytic cleavage Effects 0.000 description 3
230000001105 regulatory effect Effects 0.000 description 3
230000001177 retroviral effect Effects 0.000 description 3
238000012216 screening Methods 0.000 description 3
229910052709 silver Inorganic materials 0.000 description 3
239000004332 silver Substances 0.000 description 3
239000000243 solution Substances 0.000 description 3
230000000087 stabilizing effect Effects 0.000 description 3
239000000126 substance Substances 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 2
238000012232 AGPC extraction Methods 0.000 description 2
239000004475 Arginine Substances 0.000 description 2
108010075016 Ceruloplasmin Proteins 0.000 description 2
102100023321 Ceruloplasmin Human genes 0.000 description 2
102000012410 DNA Ligases Human genes 0.000 description 2
108010061982 DNA Ligases Proteins 0.000 description 2
102000009123 Fibrin Human genes 0.000 description 2
108010073385 Fibrin Proteins 0.000 description 2
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 2
101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 description 2
241000701109 Human adenovirus 2 Species 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
241000713869 Moloney murine leukemia virus Species 0.000 description 2
230000004988 N-glycosylation Effects 0.000 description 2
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 2
108091005804 Peptidases Proteins 0.000 description 2
108010002747 Pfu DNA polymerase Proteins 0.000 description 2
108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 2
102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 2
239000004365 Protease Substances 0.000 description 2
108010094028 Prothrombin Proteins 0.000 description 2
108091036333 Rapid DNA Proteins 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
101000865057 Thermococcus litoralis DNA polymerase Proteins 0.000 description 2
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
210000001124 body fluid Anatomy 0.000 description 2
239000010839 body fluid Substances 0.000 description 2
210000004899 c-terminal region Anatomy 0.000 description 2
238000010804 cDNA synthesis Methods 0.000 description 2
238000010805 cDNA synthesis kit Methods 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
239000000969 carrier Substances 0.000 description 2
230000003197 catalytic effect Effects 0.000 description 2
230000008859 change Effects 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
230000001112 coagulating effect Effects 0.000 description 2
238000005520 cutting process Methods 0.000 description 2
235000018417 cysteine Nutrition 0.000 description 2
125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 2
229940124447 delivery agent Drugs 0.000 description 2
XYWBJDRHGNULKG-OUMQNGNKSA-N desirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 XYWBJDRHGNULKG-OUMQNGNKSA-N 0.000 description 2
108010073652 desirudin Proteins 0.000 description 2
239000003599 detergent Substances 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
229960005542 ethidium bromide Drugs 0.000 description 2
229950003499 fibrin Drugs 0.000 description 2
230000004927 fusion Effects 0.000 description 2
108020001507 fusion proteins Proteins 0.000 description 2
102000037865 fusion proteins Human genes 0.000 description 2
230000013595 glycosylation Effects 0.000 description 2
238000006206 glycosylation reaction Methods 0.000 description 2
239000000833 heterodimer Substances 0.000 description 2
238000003018 immunoassay Methods 0.000 description 2
238000003119 immunoblot Methods 0.000 description 2
230000000951 immunodiffusion Effects 0.000 description 2
230000005847 immunogenicity Effects 0.000 description 2
239000012535 impurity Substances 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
230000002779 inactivation Effects 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
239000002502 liposome Substances 0.000 description 2
238000013507 mapping Methods 0.000 description 2
239000012528 membrane Substances 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
108091027963 non-coding RNA Proteins 0.000 description 2
102000042567 non-coding RNA Human genes 0.000 description 2
230000008488 polyadenylation Effects 0.000 description 2
230000004481 post-translational protein modification Effects 0.000 description 2
239000002987 primer (paints) Substances 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
108010012557 prothrombin complex concentrates Proteins 0.000 description 2
239000002356 single layer Substances 0.000 description 2
239000001632 sodium acetate Substances 0.000 description 2
235000017281 sodium acetate Nutrition 0.000 description 2
230000002269 spontaneous effect Effects 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
239000000758 substrate Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
235000002374 tyrosine Nutrition 0.000 description 2
230000006107 tyrosine sulfation Effects 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
238000005406 washing Methods 0.000 description 2
BBYWOYAFBUOUFP-JOCHJYFZSA-N 1-stearoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)COP(O)(=O)OCCN BBYWOYAFBUOUFP-JOCHJYFZSA-N 0.000 description 1
SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 1
NKDFYOWSKOHCCO-YPVLXUMRSA-N 20-hydroxyecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 NKDFYOWSKOHCCO-YPVLXUMRSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
101800000112 Acidic peptide Proteins 0.000 description 1
108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
102000015081 Blood Coagulation Factors Human genes 0.000 description 1
108010039209 Blood Coagulation Factors Proteins 0.000 description 1
101100275473 Caenorhabditis elegans ctc-3 gene Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000282465 Canis Species 0.000 description 1
102100037529 Coagulation factor V Human genes 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
206010010356 Congenital anomaly Diseases 0.000 description 1
108091035707 Consensus sequence Proteins 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
239000003155 DNA primer Substances 0.000 description 1
238000001712 DNA sequencing Methods 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
108700024394 Exon Proteins 0.000 description 1
108010076282 Factor IX Proteins 0.000 description 1
108010049003 Fibrinogen Proteins 0.000 description 1
102000008946 Fibrinogen Human genes 0.000 description 1
208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
241000282412 Homo Species 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
101710172064 Low-density lipoprotein receptor-related protein Proteins 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
238000009004 PCR Kit Methods 0.000 description 1
238000012408 PCR amplification Methods 0.000 description 1
239000002033 PVDF binder Substances 0.000 description 1
102000029797 Prion Human genes 0.000 description 1
108091000054 Prion Proteins 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
102100027378 Prothrombin Human genes 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
108091081021 Sense strand Proteins 0.000 description 1
239000012506 Sephacryl® Substances 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
108091081024 Start codon Proteins 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
101000712605 Theromyzon tessulatum Theromin Proteins 0.000 description 1
229940122388 Thrombin inhibitor Drugs 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
229930003448 Vitamin K Natural products 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
108700029631 X-Linked Genes Proteins 0.000 description 1
239000012190 activator Substances 0.000 description 1
239000011149 active material Substances 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
238000000246 agarose gel electrophoresis Methods 0.000 description 1
238000012867 alanine scanning Methods 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
235000021120 animal protein Nutrition 0.000 description 1
238000005349 anion exchange Methods 0.000 description 1
230000009830 antibody antigen interaction Effects 0.000 description 1
230000010100 anticoagulation Effects 0.000 description 1
239000000427 antigen Substances 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
239000000074 antisense oligonucleotide Substances 0.000 description 1
238000012230 antisense oligonucleotides Methods 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000023555 blood coagulation Effects 0.000 description 1
239000003114 blood coagulation factor Substances 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
238000005341 cation exchange Methods 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
230000004700 cellular uptake Effects 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
239000013599 cloning vector Substances 0.000 description 1
AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
238000011109 contamination Methods 0.000 description 1
239000013068 control sample Substances 0.000 description 1
238000012937 correction Methods 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
-1 delivery agent Substances 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
230000005584 early death Effects 0.000 description 1
238000010828 elution Methods 0.000 description 1
230000005966 endogenous activation Effects 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
239000006167 equilibration buffer Substances 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
238000000605 extraction Methods 0.000 description 1
229940012952 fibrinogen Drugs 0.000 description 1
230000020764 fibrinolysis Effects 0.000 description 1
239000012737 fresh medium Substances 0.000 description 1
208000030304 gastrointestinal bleeding Diseases 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
208000031209 hemophilic arthropathy Diseases 0.000 description 1
230000023597 hemostasis Effects 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
238000002513 implantation Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000012678 infectious agent Substances 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
208000014674 injury Diseases 0.000 description 1
239000003049 inorganic solvent Substances 0.000 description 1
229910001867 inorganic solvent Inorganic materials 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000007917 intracranial administration Methods 0.000 description 1
238000007852 inverse PCR Methods 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
238000012417 linear regression Methods 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
238000013160 medical therapy Methods 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
229910021645 metal ion Inorganic materials 0.000 description 1
238000003032 molecular docking Methods 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
230000035772 mutation Effects 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
238000007857 nested PCR Methods 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
229920002981 polyvinylidene fluoride Polymers 0.000 description 1
230000001581 pretranslational effect Effects 0.000 description 1
230000037452 priming Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
229940039716 prothrombin Drugs 0.000 description 1
229940024790 prothrombin complex concentrate Drugs 0.000 description 1
230000005180 public health Effects 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000010076 replication Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
238000010839 reverse transcription Methods 0.000 description 1
238000002864 sequence alignment Methods 0.000 description 1
239000012679 serum free medium Substances 0.000 description 1
230000003393 splenic effect Effects 0.000 description 1
230000010473 stable expression Effects 0.000 description 1
238000012289 standard assay Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
239000010409 thin film Substances 0.000 description 1
229960003766 thrombin (human) Drugs 0.000 description 1
239000003868 thrombin inhibitor Substances 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
230000005026 transcription initiation Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000010474 transient expression Effects 0.000 description 1
238000013519 translation Methods 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
239000001226 triphosphate Substances 0.000 description 1
235000011178 triphosphate Nutrition 0.000 description 1
UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
150000003668 tyrosines Chemical group 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
239000013603 viral vector Substances 0.000 description 1
238000011179 visual inspection Methods 0.000 description 1
235000019168 vitamin K Nutrition 0.000 description 1
239000011712 vitamin K Substances 0.000 description 1
150000003721 vitamin K derivatives Chemical class 0.000 description 1
229940046010 vitamin k Drugs 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
239000002023 wood Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/10—Factor VIII, AHF; related peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Zoology (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Medicinal Chemistry (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Physics & Mathematics (AREA)
Diabetes (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Pharmacology & Pharmacy (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Glass Compositions (AREA)
Fish Paste Products (AREA)
Steroid Compounds (AREA)

NO20024296A 2000-03-10 2002-09-09 Modifisert faktor VIII, DNA, ekspresjonsvektor, terapeutisk preparat, metode for a produsere modifisert svin-faktor VIII-protein, samt vertcelle NO331935B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US09/523,656 US6458563B1 (en)	1996-06-26	2000-03-10	Modified factor VIII
PCT/US2001/005076 WO2001068109A1 (fr)	2000-03-10	2001-02-16	Facteur viii modifie

Publications (3)

Publication Number	Publication Date
NO20024296D0 NO20024296D0 (no)	2002-09-09
NO20024296L NO20024296L (no)	2002-11-08
NO331935B1 true NO331935B1 (no)	2012-05-07

Family

ID=24085870

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO20024296A NO331935B1 (no)	2000-03-10	2002-09-09	Modifisert faktor VIII, DNA, ekspresjonsvektor, terapeutisk preparat, metode for a produsere modifisert svin-faktor VIII-protein, samt vertcelle
NO2016007C NO2016007I1 (no)	2000-03-10	2016-05-10	Susoktokog

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NO2016007C NO2016007I1 (no)	2000-03-10	2016-05-10	Susoktokog

Country Status (35)

Country	Link
US (3)	US6458563B1 (fr)
EP (1)	EP1280540B1 (fr)
JP (1)	JP4044337B2 (fr)
KR (1)	KR100485525B1 (fr)
CN (1)	CN1191360C (fr)
AT (1)	ATE391512T1 (fr)
AU (2)	AU2001238416B2 (fr)
BE (1)	BE2016C024I2 (fr)
BR (2)	BRPI0109131B8 (fr)
CA (1)	CA2400295C (fr)
CY (2)	CY1108179T1 (fr)
CZ (1)	CZ298250B6 (fr)
DE (1)	DE60133541T2 (fr)
DK (1)	DK1280540T3 (fr)
EE (1)	EE05075B1 (fr)
ES (1)	ES2304379T3 (fr)
FR (1)	FR16C0016I2 (fr)
HU (2)	HU227804B1 (fr)
IL (2)	IL151371A0 (fr)
LT (1)	LTC1280540I2 (fr)
LU (1)	LU93049I2 (fr)
ME (1)	MEP8209A (fr)
MX (1)	MXPA02008798A (fr)
NL (1)	NL300808I2 (fr)
NO (2)	NO331935B1 (fr)
NZ (1)	NZ520799A (fr)
PL (1)	PL202936B1 (fr)
PT (1)	PT1280540E (fr)
RS (1)	RS50364B (fr)
RU (1)	RU2285724C2 (fr)
SI (1)	SI1280540T1 (fr)
SK (1)	SK286205B6 (fr)
UA (1)	UA75064C2 (fr)
WO (1)	WO2001068109A1 (fr)
ZA (1)	ZA200206810B (fr)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7560107B2 (en) *	1996-06-26	2009-07-14	Emory University	Modified factor VIII
WO2002060951A2 (fr) *	2001-01-12	2002-08-08	The American National Red Cross	Methodes et compositions permettant de reduire la clairance du facteur viii, mediee par l'heparan-sulfate proteoglycane
EP1572889B1 (fr) *	2001-10-05	2008-12-17	Expression Therapeutics, LLC	Sequences d'acides nucleiques et d'acides amines codant des polypeptides de facteur viii a expresseur a haut rendement et leurs procedes d'utilisation
US20040249134A1 (en) *	2001-11-30	2004-12-09	Lollar John S.	Factor viii c2 domain variants
GB0207092D0 (en) *	2002-03-26	2002-05-08	Sod Conseils Rech Applic	Stable pharmaceutical composition containing factor VIII
TWI353991B (en)	2003-05-06	2011-12-11	Syntonix Pharmaceuticals Inc	Immunoglobulin chimeric monomer-dimer hybrids
US7485291B2 (en) *	2003-06-03	2009-02-03	Cell Genesys, Inc.	Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
JP4644663B2 (ja) *	2003-06-03	2011-03-02	セルジェネシスインコーポレイテッド	ペプチド開裂部位を用いた単一ベクターからの組換えポリペプチドの高められた発現のための構成と方法
US7541439B2 (en) *	2003-06-26	2009-06-02	Merck Patent Gmbh	Thrombopoietin proteins with improved properties
US20050059023A1 (en) *	2003-09-16	2005-03-17	Cantor Thomas L.	Methods and kits for monitoring resistance to therapeutic agents
US7211559B2 (en)	2003-10-31	2007-05-01	University Of Maryland, Baltimore	Factor VIII compositions and methods
WO2005055930A2 (fr) *	2003-12-03	2005-06-23	University Of Rochester	Facteur viii recombine presentant une activite specifique amelioree
DK1750733T3 (da) *	2004-05-03	2014-01-20	Univ Emory	FREMGANGSMÅDE TIL INDGIVELSE AF SVINE-B-DOMÆNELØS fVIII
WO2005123928A1 (fr) *	2004-06-08	2005-12-29	Battelle Memorial Institute	Production du facteur viii de coagulation humain à partir de cellules végétales et de plantes entières
KR101468345B1 (ko) *	2004-11-12	2014-12-03	바이엘 헬스케어 엘엘씨	Ｆｖｉｉｉ의 부위 지향 변형
WO2006063031A2 (fr)	2004-12-06	2006-06-15	Haplomics	Variants alleliques du facteur viii humain
US7855279B2 (en)	2005-09-27	2010-12-21	Amunix Operating, Inc.	Unstructured recombinant polymers and uses thereof
WO2007065691A2 (fr)	2005-12-07	2007-06-14	Technische Universität München	Petits ligands d'affinite peptidiques et peptido-mimetiques pour le facteur viii et pour des proteines similaires au facteur viii
EP1816201A1 (fr)	2006-02-06	2007-08-08	CSL Behring GmbH	Facteur de coagulation VIIa modifié ayant une stabilité 'half-life' améliorée
US20100222554A1 (en) *	2006-04-11	2010-09-02	Thomas Weimer	Method of Increasing the In Vivo Recovery of Therapeutic Polypeptides
US7939632B2 (en) *	2006-06-14	2011-05-10	Csl Behring Gmbh	Proteolytically cleavable fusion proteins with high molar specific activity
EP1935430A1 (fr) *	2006-12-22	2008-06-25	CSL Behring GmbH	Facteurs de coagulation modifiés avec une demi-vie in vivo prolongée
KR101542752B1 (ko) *	2006-12-22	2015-08-10	체에스엘 베링 게엠베하	연장된 생체내 반감기를 갖는 변형된 응고 인자
FR2913020B1 (fr) *	2007-02-23	2012-11-23	Biomethodes	Nouveaux facteurs viii pour le traitement des hemophiles de type a
EP1988101A1 (fr) *	2007-05-04	2008-11-05	Novo Nordisk A/S	Amélioration des titres de polypeptide de facteur VIII dans les cultures cellulaires
CN104152489A (zh)	2007-11-01	2014-11-19	罗切斯特大学	具有增加的稳定性的重组因子viii
EP2149603A1 (fr)	2008-07-28	2010-02-03	DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH	Variantes du facteur IX dotées d'activité de coagulation en l'absence de leur cofacteur et leur utilisation pour le traitement de troubles du sang
JP5843357B2 (ja)	2009-02-03	2016-01-13	アムニクスオペレーティングインコーポレイテッド	延長組換えポリペプチドおよび延長組換えポリペプチドを含む組成物
HRP20171480T1 (hr)	2009-06-09	2018-01-12	Prolong Pharmaceuticals, LLC	Kompozicije hemoglobina
JP2013502458A (ja)	2009-08-24	2013-01-24	アムニクスオペレーティングインコーポレイテッド	凝固第ｖｉｉ因子組成物ならびにそれを製造および使用する方法
CA2780763A1 (fr) *	2009-11-13	2011-05-19	Puget Sound Blood Center	Variants d'epitopes des lymphocytes t du facteur viii a immunogenicite reduite
KR101770849B1 (ko)	2009-12-06	2017-09-05	바이오버라티브 테라퓨틱스 인크.	인자 ＦⅧ-Ｆｃ의 키메라 및 하이브리드 폴리펩티드, 및 그의 사용방법
EP2524054A2 (fr) *	2010-01-14	2012-11-21	Haplomics, Inc.	Prédiction et réduction de l'allo-immunogénicité des agents thérapeutiques protéiques
EA201291482A1 (ru)	2010-07-09	2013-10-30	Байоджен Айдек Хемофилия Инк.	Химерные факторы коагуляции
WO2012006623A1 (fr)	2010-07-09	2012-01-12	Biogen Idec Hemophilia Inc.	Systèmes pour le traitement du facteur viii et procédés associés
JP5922141B2 (ja)	2010-11-05	2016-05-24	バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒＩｎｔｅｒｎａｔｉｏｎａｌＩｎｃｏｒｐ０Ｒａｔｅｄ	増加した比活性を有する抗血友病第ｖｉｉｉ因子の新規変異体
EP2661488A1 (fr) *	2011-01-05	2013-11-13	Expression Therapeutics, LLC	Procédé et système pour la culture cellulaire en suspension
EP3527218A1 (fr)	2011-06-10	2019-08-21	Bioverativ Therapeutics Inc.	Composés procoagulants et procédés d'utilisation correspondants
HRP20190535T1 (hr)	2011-07-08	2019-05-17	Bioverativ Therapeutics Inc.	Kimerni i hibridni polipeptidi faktora viii i postupci njihove upotrebe
WO2013016454A1 (fr)	2011-07-25	2013-01-31	Biogen Idec Hemophilia Inc.	Dosages pour la surveillance de troubles hémostatiques
CN102277379B (zh) *	2011-08-18	2013-07-24	中国科学院遗传与发育生物学研究所	表达凝血因子viii的表达载体及其应用
KR102212098B1 (ko)	2012-01-12	2021-02-03	바이오버라티브 테라퓨틱스 인크.	키메라 인자 viii 폴리펩티드들과 이의 용도
EA029560B1 (ru)	2012-01-12	2018-04-30	Байоджен Эмэй Инк.	Применение химерного фактора свертывания крови для уменьшения ингибирующего иммунного ответа у субъекта
MX369862B (es)	2012-02-15	2019-11-25	Bioverativ Therapeutics Inc	Composiciones del factor viii y metodos para hacerlas y usarlas.
JP6383666B2 (ja)	2012-02-15	2018-08-29	バイオベラティブセラピューティクスインコーポレイテッド	組換え第ｖｉｉｉ因子タンパク質
EP2666782A1 (fr) *	2012-05-22	2013-11-27	Imnate Sarl	Facteur VIII de coagulation avec immunogénicité réduite
JP2015525222A (ja)	2012-06-08	2015-09-03	バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎＭＡＩｎｃ．	キメラ性凝固因子
EP4079316A1 (fr)	2012-06-08	2022-10-26	Bioverativ Therapeutics Inc.	Composés procoagulants
US10023628B2 (en)	2012-07-06	2018-07-17	Bioverativ Therapeutics Inc.	Cell line expressing single chain factor VIII polypeptides and uses thereof
EA201792485A3 (ru)	2012-07-11	2019-03-29	Амуникс Оперэйтинг Инк.	Комплекс фактора viii с xten и белком-фактором фон виллебранда, и его применение (варианты)
EP3970738A1 (fr)	2012-07-25	2022-03-23	Bioverativ Therapeutics Inc.	Essai de surveillance de facteur sanguin et utilisations de celui-ci
AU2013331000B2 (en)	2012-10-18	2018-04-19	Bioverativ Therapeutics Inc.	Methods of using a fixed dose of a clotting factor
EP3943102A1 (fr)	2012-10-30	2022-01-26	Bioverativ Therapeutics Inc.	Procédé d'utilisation de polypeptide du facteur viii
US10272163B2 (en)	2012-12-07	2019-04-30	The Regents Of The University Of California	Factor VIII mutation repair and tolerance induction
PL2956477T5 (pl)	2013-02-15	2024-05-27	Bioverativ Therapeutics Inc.	Zoptymalizowany gen czynnika viii
AU2014228506A1 (en)	2013-03-15	2015-08-13	Bioverativ Therapeutics Inc.	Factor VIII polypeptide formulations
SG10201707600XA (en)	2013-03-15	2017-11-29	Biogen Ma Inc	Factor ix polypeptide formulations
US20160251408A1 (en)	2013-06-28	2016-09-01	Biogen Ma Inc.	Thrombin cleavable linker with xten and its uses thereof
EP3875106A1 (fr)	2013-08-08	2021-09-08	Bioverativ Therapeutics Inc.	Purification des molécules fviii chimériques
TWI667255B (zh)	2013-08-14	2019-08-01	美商生物化學醫療公司	因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
BR112016009064A2 (pt)	2013-10-22	2017-09-19	Inst Nat Sante Rech Med	Dispositivo de emplastro cutâneo; sistema de liberação de fármaco; kit; e método de tratamento da hemofilia em um indivíduo em necessidade do mesmo
EP3065769A4 (fr)	2013-11-08	2017-05-31	Biogen MA Inc.	Composé de fusion procoagulant
EP4332839A3 (fr)	2013-12-06	2024-06-05	Bioverativ Therapeutics Inc.	Outils pharmacocinétiques de population et leurs utilisations
EP2881463A1 (fr)	2013-12-09	2015-06-10	DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH	Variants du facteur IX présentant une activité de coagulation en l'absence de leur cofacteur et/ou à une activité de coagulation F.IX accrue et leur utilisation pour traiter des troubles de saignement
MY204756A (en)	2014-01-10	2024-09-11	Bioverativ Therapeutics Inc	Factor viii chimeric proteins and uses thereof
JP6609561B2 (ja)	2014-02-04	2019-11-20	バイオジェン・エムエイ・インコーポレイテッド	翻訳後修飾を濃縮するための、フロースルーモードにおける陽イオン交換クロマトグラフィーの使用
US20170051041A1 (en) *	2014-02-19	2017-02-23	Kathleen Pratt	Factor viii b cell epitope variants having reduced immunogenicity
WO2015132724A1 (fr)	2014-03-05	2015-09-11	Pfizer Inc.	Mutéines améliorées du facteur viii de coagulation
US11008561B2 (en)	2014-06-30	2021-05-18	Bioverativ Therapeutics Inc.	Optimized factor IX gene
MA40864A (fr)	2014-10-31	2017-09-05	Biogen Ma Inc	Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
IL257231B (en)	2015-08-03	2022-09-01	Bioverativ Therapeutics Inc	Factor ix fusion proteins and methods of making and using same
PE20231949A1 (es) *	2015-10-30	2023-12-05	Spark Therapeutics Inc	VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA
TWI850587B (zh)	2015-11-13	2024-08-01	日商武田藥品工業股份有限公司	用於ａ型血友病基因治療之編碼表現增加之重組ｆｖｉｉｉ變異體之病毒載體
EA202190827A1 (ru)	2015-11-13	2021-11-30	Баксалта Инкорпорейтед	Вирусные векторы, кодирующие рекомбинантные варианты fviii с повышенной экспрессией для генной терапии гемофилии a
RS63548B1 (sr)	2016-02-01	2022-09-30	Bioverativ Therapeutics Inc	Optimizovani geni faktora viii
WO2017222337A1 (fr)	2016-06-24	2017-12-28	재단법인 목암생명과학연구소	Protéine chimère comprenant les facteurs fviii et vwf, et utilisation de celle-ci
CN110520150A (zh)	2016-12-02	2019-11-29	比奥维拉迪维治疗股份有限公司	使用嵌合凝血因子治疗血友病性关节病的方法
CA3044838A1 (fr)	2016-12-02	2018-06-07	Bioverativ Therapeutics Inc.	Procedes d'induction de tolerance immunitaire a des facteurs de coagulation
JP2020519272A (ja) *	2017-05-09	2020-07-02	エモリーユニバーシティー	凝固因子変異体及びその使用
KR20250040746A (ko)	2017-08-09	2025-03-24	바이오버라티브 테라퓨틱스 인크.	핵산 분자 및 이의 용도
CN111918674A (zh)	2018-02-01	2020-11-10	比奥维拉迪维治疗股份有限公司	表达因子viii的慢病毒载体的用途
CN112203646A (zh)	2018-04-04	2021-01-08	西吉隆医疗股份有限公司	可植入颗粒和相关方法
LT3793588T (lt)	2018-05-18	2025-06-25	Bioverativ Therapeutics Inc.	Hemofilijos a gydymo būdai
CA3106590A1 (fr)	2018-07-16	2020-01-23	Baxalta Incorporated	Therapie genique de l'hemophilie a l'aide de vecteurs viraux codant des variants de fviii recombinants presentant une expression accrue
JP7602454B2 (ja)	2018-08-09	2024-12-18	バイオベラティブセラピューティクスインコーポレイテッド	核酸分子及び非ウイルス遺伝子治療のためのそれらの使用
UY38389A (es)	2018-09-27	2020-04-30	Sigilon Therapeutics Inc	Dispositivos implantables para terapia celular y métodos relacionados
TWI851647B (zh)	2019-01-16	2024-08-11	日商武田藥品工業股份有限公司	用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
TW202115127A (zh)	2019-06-19	2021-04-16	美商百歐維拉提夫治療公司	治療血友病及低骨質密度之方法及組成物
JP2022537555A (ja)	2019-06-20	2022-08-26	武田薬品工業株式会社	ウイルスベースの遺伝子療法による治療方法
US12403164B2 (en)	2019-09-30	2025-09-02	Bioverativ Therapeutics Inc.	Lentiviral vector formulations
EP4073106A2 (fr)	2019-12-12	2022-10-19	Takeda Pharmaceutical Company Limited	Thérapie génique de l'hémophilie à l'aide de vecteurs viraux codant des variants de fviii recombinants présentant une expression accrue
BR112022026127A2 (pt)	2020-06-24	2023-01-17	Bioverativ Therapeutics Inc	Métodos para remoção de fator viii livre de preparações de vetores lentivirais modificados para expressar referida proteína
TW202246505A (zh) *	2021-03-05	2022-12-01	俄羅斯聯邦商亞那拜恩有限公司	編碼凝血因子ｉｘ蛋白的密碼子優化的核酸及其用途
US11906532B2 (en)	2021-03-31	2024-02-20	Haemonetics Corporation	Hemostasis measurement device quality control formulations
CN117858895A (zh)	2021-06-14	2024-04-09	武田药品工业株式会社	使用表达增强的编码重组fviii变体的病毒载体的血友病a基因疗法
TW202323274A (zh)	2021-08-23	2023-06-16	美商百歐維拉提夫治療公司	優化因子viii基因
AU2022355088A1 (en)	2021-09-30	2024-05-16	Bioverativ Therapeutics Inc.	Nucleic acids encoding factor viii polypeptides with reduced immunogenicity
JP2025534659A (ja)	2022-10-11	2025-10-17	シギロンセラピューティクス，インコーポレイテッド	疾患治療のための改変細胞及び移植可能エレメント
WO2025008774A1 (fr)	2023-07-05	2025-01-09	Takeda Pharmaceutical Company Limited	Vecteurs viraux codant pour des variants de fviii recombinants ayant une expression accrue pour la thérapie génique de l'hémophilie a

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4757006A (en)	1983-10-28	1988-07-12	Genetics Institute, Inc.	Human factor VIII:C gene and recombinant methods for production
EP0182448A3 (fr)	1984-08-24	1987-10-28	Genetics Institute, Inc.	Production de facteur VIII et produits apparentés
EP0218712B1 (fr)	1985-04-12	1992-02-26	Genetics Institute, Inc.	Nouvelles proteines procoagulantes
JPH0387173A (ja)	1987-09-10	1991-04-11	Teijin Ltd	ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
DK162233C (da)	1989-11-09	1992-03-16	Novo Nordisk As	Fremgangsmaade til isolering af faktor viii fra blodplasma og pharmaceutisk praeparat indeholdende den saaledes isolerede fator viii
MC2211A1 (fr) *	1989-12-01	1992-11-26	Genpharm Int	Production de polypeptides recombinants par une espece bovine et procedes transgeniques
US6180371B1 (en) *	1996-06-26	2001-01-30	Emory University	Modified factor VIII
US5663060A (en)	1992-04-07	1997-09-02	Emory University	Hybrid human/animal factor VIII
US5364771A (en)	1992-04-07	1994-11-15	Emory University	Hybrid human/porcine factor VIII
US5563045A (en)	1992-11-13	1996-10-08	Genetics Institute, Inc.	Chimeric procoagulant proteins
WO1997003193A1 (fr)	1995-07-11	1997-01-30	Chiron Corporation	Nouveaux analogues du polypeptide du facteur viii:c presentant des proprietes modifiees de liaison avec des metaux
AU6291896A (en)	1995-07-11	1997-02-10	Chiron Corporation	Novel factor viii:c polypeptide analogs comprising factor v domains or subdomains
US6770744B2 (en) *	2000-09-19	2004-08-03	Emory University	Modified factor VIII
US20040249134A1 (en) *	2001-11-30	2004-12-09	Lollar John S.	Factor viii c2 domain variants
US7105745B2 (en) *	2002-12-31	2006-09-12	Thomas & Betts International, Inc.	Water resistant electrical floor box cover assembly

2000
- 2000-03-10 US US09/523,656 patent/US6458563B1/en not_active Expired - Lifetime
2001
- 2001-02-16 EP EP01910853A patent/EP1280540B1/fr not_active Expired - Lifetime
- 2001-02-16 AU AU2001238416A patent/AU2001238416B2/en active Active
- 2001-02-16 AT AT01910853T patent/ATE391512T1/de active
- 2001-02-16 HU HU0300586A patent/HU227804B1/hu active Protection Beyond IP Right Term
- 2001-02-16 EE EEP200200510A patent/EE05075B1/xx active Protection Beyond IP Right Term
- 2001-02-16 WO PCT/US2001/005076 patent/WO2001068109A1/fr not_active Ceased
- 2001-02-16 BR BRPI0109131A patent/BRPI0109131B8/pt not_active IP Right Cessation
- 2001-02-16 MX MXPA02008798A patent/MXPA02008798A/es active IP Right Grant
- 2001-02-16 IL IL15137101A patent/IL151371A0/xx unknown
- 2001-02-16 RU RU2002124123/13A patent/RU2285724C2/ru active
- 2001-02-16 BR BR122013026957A patent/BR122013026957A8/pt not_active Application Discontinuation
- 2001-02-16 PL PL359672A patent/PL202936B1/pl unknown
- 2001-02-16 AU AU3841601A patent/AU3841601A/xx active Pending
- 2001-02-16 DK DK01910853T patent/DK1280540T3/da active
- 2001-02-16 SK SK1439-2002A patent/SK286205B6/sk not_active IP Right Cessation
- 2001-02-16 ES ES01910853T patent/ES2304379T3/es not_active Expired - Lifetime
- 2001-02-16 RS YUP-680/02A patent/RS50364B/sr unknown
- 2001-02-16 CZ CZ20023346A patent/CZ298250B6/cs unknown
- 2001-02-16 JP JP2001566673A patent/JP4044337B2/ja not_active Expired - Lifetime
- 2001-02-16 NZ NZ520799A patent/NZ520799A/en not_active IP Right Cessation
- 2001-02-16 KR KR10-2002-7011843A patent/KR100485525B1/ko not_active Expired - Lifetime
- 2001-02-16 PT PT01910853T patent/PT1280540E/pt unknown
- 2001-02-16 CA CA2400295A patent/CA2400295C/fr not_active Expired - Lifetime
- 2001-02-16 DE DE60133541T patent/DE60133541T2/de not_active Expired - Lifetime
- 2001-02-16 CN CNB018063179A patent/CN1191360C/zh not_active Expired - Lifetime
- 2001-02-16 UA UA2002097145A patent/UA75064C2/uk unknown
- 2001-02-16 SI SI200130823T patent/SI1280540T1/sl unknown
- 2001-02-16 ME MEP-82/09A patent/MEP8209A/xx unknown
2002
- 2002-06-28 US US10/187,319 patent/US7012132B2/en not_active Expired - Fee Related
- 2002-08-21 IL IL151371A patent/IL151371A/en active IP Right Grant
- 2002-08-26 ZA ZA200206810A patent/ZA200206810B/en unknown
- 2002-09-09 NO NO20024296A patent/NO331935B1/no not_active IP Right Cessation
2004
- 2004-09-10 US US10/938,414 patent/US7122634B2/en not_active Expired - Fee Related
2008
- 2008-07-07 CY CY20081100709T patent/CY1108179T1/el unknown
2016
- 2016-04-27 LU LU93049C patent/LU93049I2/fr unknown
- 2016-04-29 FR FR16C0016C patent/FR16C0016I2/fr active Active
- 2016-05-02 BE BE2016C024C patent/BE2016C024I2/fr unknown
- 2016-05-06 LT LTPA2016014C patent/LTC1280540I2/lt unknown
- 2016-05-09 NL NL300808C patent/NL300808I2/nl unknown
- 2016-05-09 HU HUS1600020C patent/HUS1600020I1/hu unknown
- 2016-05-10 CY CY2016011C patent/CY2016011I2/el unknown
- 2016-05-10 NO NO2016007C patent/NO2016007I1/no unknown

Also Published As

Publication number	Publication date
US7122634B2 (en)	2006-10-17
CA2400295C (fr)	2012-01-10
SK286205B6 (sk)	2008-05-06
ATE391512T1 (de)	2008-04-15
NO2016007I2 (no)	2016-05-10
CY1108179T1 (el)	2014-02-12
FR16C0016I1 (fr)	2016-04-29
CN1416348A (zh)	2003-05-07
CZ20023346A3 (cs)	2003-01-15
DE60133541T2 (de)	2009-05-07
YU68002A (sh)	2005-11-28
PT1280540E (pt)	2008-06-09
HK1051004A1 (en)	2003-07-18
NO2016007I1 (no)	2016-05-10
LU93049I2 (fr)	2016-06-27
NO20024296D0 (no)	2002-09-09
RU2285724C2 (ru)	2006-10-20
FR16C0016I2 (fr)	2018-11-02
PL202936B1 (pl)	2009-08-31
US7012132B2 (en)	2006-03-14
MXPA02008798A (es)	2003-04-25
JP2003526358A (ja)	2003-09-09
NL300808I2 (nl)	2020-12-21
HUP0300586A2 (hu)	2003-06-28
IL151371A0 (en)	2003-04-10
EE200200510A (et)	2004-02-16
RS50364B (sr)	2009-11-10
PL359672A1 (en)	2004-09-06
BRPI0109131B8 (pt)	2021-07-06
EP1280540A1 (fr)	2003-02-05
EE05075B1 (et)	2008-10-15
HU227804B1 (en)	2012-03-28
BR0109131A (pt)	2004-12-07
NL300808I1 (fr)	2016-05-18
CA2400295A1 (fr)	2001-09-20
HUP0300586A3 (en)	2006-11-28
DE60133541D1 (de)	2008-05-21
SI1280540T1 (sl)	2008-08-31
CN1191360C (zh)	2005-03-02
CY2016011I1 (el)	2016-10-05
WO2001068109A1 (fr)	2001-09-20
BRPI0109131B1 (pt)	2020-08-25
US20030068785A1 (en)	2003-04-10
ME00601B (fr)	2011-12-20
JP4044337B2 (ja)	2008-02-06
EP1280540B1 (fr)	2008-04-09
UA75064C2 (en)	2006-03-15
LTC1280540I2 (lt)	2020-05-25
AU2001238416B2 (en)	2004-09-02
MEP8209A (en)	2011-12-20
CY2016011I2 (el)	2016-10-05
NZ520799A (en)	2004-06-25
HUS1600020I1 (hu)	2016-06-28
SK14392002A3 (sk)	2003-06-03
BR122013026957A2 (fr)	2004-12-07
US20050079584A1 (en)	2005-04-14
ZA200206810B (en)	2003-11-26
BR122013026957A8 (pt)	2017-02-21
IL151371A (en)	2010-12-30
AU3841601A (en)	2001-09-24
KR100485525B1 (ko)	2005-04-28
EP1280540A4 (fr)	2004-11-03
ES2304379T3 (es)	2008-10-16
DK1280540T3 (da)	2008-07-14
NO20024296L (no)	2002-11-08
KR20020081426A (ko)	2002-10-26
CZ298250B6 (cs)	2007-08-01
US6458563B1 (en)	2002-10-01
RU2002124123A (ru)	2004-03-27
BE2016C024I2 (fr)	2020-01-30

Publication	Publication Date	Title
NO331935B1 (no)	2012-05-07	Modifisert faktor VIII, DNA, ekspresjonsvektor, terapeutisk preparat, metode for a produsere modifisert svin-faktor VIII-protein, samt vertcelle
AU2001238416A1 (en)	2001-12-06	Modified factor VIII
EP1200105B1 (fr)	2005-03-30	Facteur viii modifie
US8951515B2 (en)	2015-02-10	Modified factor VIII
WO1997049725A9 (fr)	2005-11-17	Facteur viii modifie
AU2995699A (en)	1999-09-27	Modified factor viii
JP2005518783A (ja)	2005-06-30	高レベルエキスプレッサー第ｖｉｉｉ因子ポリペプチドをコードする核酸配列およびアミノ酸配列および使用方法
AU2002364509A1 (en)	2003-06-17	Factor viii c2 domain variants
HK1051004B (en)	2009-01-30	Modified factor viii
MXPA00008829A (en)	2002-02-26	Modified factor viii
HK1043543B (en)	2005-09-09	Modified factor viii

Legal Events

Date	Code	Title	Description
2016-05-23	SPCF	Filing of supplementary protection certificate	Free format text: PRODUCT NAME: SUSOKTOKOG; NAT. REG. NO/DATE: EU/1/15/1035 20151130; FIRST REG. NO/DATE: EU/1/15/1035/001-003 20151111 Spc suppl protection certif: 2016007 Filing date: 20160510
2018-07-02	SPCG	Granted supplementary protection certificate	Free format text: PRODUCT NAME: SUSOKTOKOG; NAT. REG. NO/DATE: EU/1/15/1035 20151130; FIRST REG. NO/DATE: EU/1/15/1035/001-003 20151111 Spc suppl protection certif: 2016007 Filing date: 20160510 Extension date: 20260216
2021-03-08	MK1K	Patent expired

Date

Code

Title

Description

2016-05-23

SPCF

Filing of supplementary protection certificate

Free format text: PRODUCT NAME: SUSOKTOKOG; NAT. REG. NO/DATE: EU/1/15/1035 20151130; FIRST REG. NO/DATE: EU/1/15/1035/001-003 20151111

Spc suppl protection certif: 2016007

Filing date: 20160510

2018-07-02

SPCG

Granted supplementary protection certificate